Bridget McKay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bridget McKay has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Benjamin A. Blizard
Mammoth Biosciences, Inc. Brisbane California USA
1 shared publication- Carley G. Hendriks
Mammoth Biosciences, Inc., 1000 Marina Blvd, Suite 600, Brisbane, CA 94005, USA
1 shared publication Deepika Verma
Mammoth Biosciences, Inc. Brisbane California USA
1 shared publication- Elizabeth M. Hawkins
Mammoth Biosciences, Inc. Brisbane California USA
1 shared publication - Emel Alpay
Mammoth Biosciences, Inc., 1000 Marina Blvd, Suite 600, Brisbane, CA 94005, USA
1 shared publication - Emma G. Stanfield
Department of Ecology & Evolution, The University of Chicago
1 shared publication
Latest Publications
- Open Access
- 10 September 2021
- Published by Wiley in Biotechnology Journal
- Vol. 17 (7) , 2100304
CRISPR‐Cas enzymes: The toolkit revolutionizing diagnostics
The programmable nature of sequence‐specific targeting by CRISPR‐Cas nucleases has revolutionized a wide range of genomic applications and is now emerging as a method for nucleic acid detection. We explore how the diversity of CRISPR systems and their fundamental mechanisms have given rise to a wave of new methods for target recognition and readout. These cross‐disciplinary advances found at the intersection of CRISPR biology and engineering have led to the ability to rapidly generate solutions for emerging global challenges like the COVID‐19 pandemic. We further discuss the advances and potential for CRISPR‐based detection to have an impact across a continuum of diagnostic applications.
- 10 September 2021
- Published by Wiley in Biotechnology Journal
- Vol. 17 (7) , 2100304
Open AccessCRISPR‐Cas enzymes: The toolkit revolutionizing diagnostics
The programmable nature of sequence‐specific targeting by CRISPR‐Cas nucleases has revolutionized a wide range of genomic applications and is now emerging as a method for nucleic acid detection. We explore how the diversity of CRISPR systems and their fundamental mechanisms have given rise to a wave of new methods for target recognition and readout. These cross‐disciplinary advances found at the intersection of CRISPR biology and engineering have led to the ability to rapidly generate solutions for emerging global challenges like the COVID‐19 pandemic. We further discuss the advances and potential for CRISPR‐based detection to have an impact across a continuum of diagnostic applications.